Nolan Sean P. 4
4 · Taysha Gene Therapies, Inc. · Filed Sep 30, 2020
Insider Transaction Report
Form 4
Nolan Sean P.
DirectorChief Executive Officer
Transactions
- Conversion
Series A Preferred Stock
2020-09-28−1,000,000→ 0 total(indirect: See Footnote)→ Common Stock (1,089,500 underlying) - Conversion
Common Stock
2020-09-28+1,089,500→ 1,089,500 total(indirect: See Footnote) - Conversion
Common Stock
2020-09-28+1,601→ 1,091,101 total(indirect: See Footnote) - Conversion
Series B Preferred Stock
2020-09-28−1,470→ 0 total(indirect: See Footnote)→ Common Stock (1,601 underlying)
Footnotes (2)
- [F1]Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date.
- [F2]The securities are held by Nolan Capital, LLC (the "LLC"). The Reporting Person is the President of LLC, and is deemed to have sole voting and investment power with respect to the securities.